Trial and cure-program status families can track.
Built from ClinicalTrials.gov status on programs we watch. Type1Cure never implies you are eligible — talk with your care team before any trial decision.
Programs with recruiting activity
From the live cure pipeline (8 programs tracked). Always verify on the registry page.
Recent trial feed items
METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
RECRUITING, PHASE2. Interventions: AMX0035, Placebo. Locations: Seattle, Washington, United States | Amsterdam, Netherlands. The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between the University of Washington and Amsterdam University M...
Changes in Person-reported Outcomes and Behavior Using the Accu-Chek SmartGuide CGM and Predict App
RECRUITING, NA. Interventions: SmartGuide CGM without Predict App, SmartGuide CGM with Predict App. Locations: Bad Mergentheim, Baden-Wurttemberg, Germany. The goal of this controlled pre-post-trial is to test the Accu-Chek SmartGuide continuous glucose monitoring (CGM) system and whether its predictive features provide additional benefits for adults with type 1 diabetes or insulin- treated type 2 diabetes. The main questions this study aims to answer are...
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
RECRUITING, PHASE2. Interventions: ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs), Anti-CD20 (rituximab), Placebo. Locations: Bialystok, Poland | Gdansk, Poland | Katowice, Poland. The main purpose of the study is to check: * Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or delay type 1 diabetes? * Is thera...
Long Term Follow up of Recipients of Functional Islet Allografts
RECRUITING. Locations: Miami, Florida, United States. Since its inception, the Diabetes Research Institute (DRI) has made significant contributions to the field of diabetes, pioneering many of the techniques used in diabetes centers around the world. Through several clinical trials, DRI has demonstrated that diabetes can be successfully reversed as a result of islet cell transplant. Over the years the following protocols in islet cell transplantation have...
Dysautonomia in Children With Type 1 Diabetes
RECRUITING, NA. Interventions: Neurocoach® and Sudoscan®. Locations: Saint-Etienne, France. Some physiological factors, such as physical activity, or pathological factors, such as sepsis or diabetes, are known to modulate the overall autonomic activity and the individual's intrinsic capacity to regulate their sympathetic and parasympathetic balance. These conditions can alter the physiological autonomic balance, sometimes with positive consequences on the...
Type 1 Diabetes and Obstructive Sleep Apnea
RECRUITING, NA. Interventions: Continuous positive airway pressure (CPAP). Locations: Chicago, Illinois, United States. The purpose of the study is to investigate the role of sleep apnea in glycemic dysregulation in adults with Type 1 diabetes.
Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State
RECRUITING, PHASE1. Interventions: GZR-33. Locations: Neuss, Germany | Neuss, Germany. This trial intends to investigate the pharmacodynamics, pharmacokinetics, safety, and tolerability of insulin GZR33 (hereafter referred to as GZR33) and estimate its potency in comparison with insulin degludec.
Immunotherapy with Autologous Tregs in T1DM
RECRUITING, PHASE1. Interventions: Ex vivo Expanded Human Autologous Regulatory T Cells, Routine Care. Locations: Nanjing, Jiangsu, China. Type 1 diabetes (T1D) is an autoimmune disease characterized by a progressive immune distruction of pancreat beta cells and deterioration of endogenous insulin secretion. Regulatory T cells (Treg) are fuctionally deficient in T1D, leading to the loss of immune tolerance to the islets and the initiation of an autoimmune...
Also on the tracker
- VX-264 (encapsulated islet cells)Early clinical trial
- Hypoimmune islet cells (UP421 / SC451)First-in-human / early research
- Cell Pouch islet transplantClinical trial
- Tegoprubart (immune protection)Clinical trial
- Teplizumab (Tzield)FDA approved (delays onset)
- KRIYA-839 gene therapyPreclinical
- Gene-edited cell replacementEarly research
These are research programs pursuing a functional cure or disease modification for type 1 diabetes. None is a confirmed, broadly available cure. Trial status is informational, not medical advice, and not a recruiting offer. Verify eligibility and details with the official trial record and a clinician.